Printer Friendly

VASCULAR TESTING INDUSTRY UNITES TO FORM THE ASSOCIATION FOR COST-EFFECTIVE CARDIOVASCULAR TECHNOLOGY

 GOLDEN, Colo., July 27 /PRNewswire/ -- The Association for Cost- effective Cardiovascular Technology (ACCT) has been established to educate state, federal and private sector representatives on issues concerning the vascular testing industry. The new organization, founded by Imex Medical Systems Inc. (NASDAQ: IMEX), Golden, was formed with the support of several industry experts and seven other vascular products manufacturers.
 "With serious discussions in Washington bound to effect change throughout the healthcare industry, we felt it was imperative that the voice of the vascular testing industry be heard," said Ernie Malachowski, ACCT executive director. "We feel that responsible early testing of vascular diseases can reduce the total cost of healthcare. The industry is eager to work together to manage the changes that are expected with healthcare reform."
 The goals of the ACCT are to:
 -- Provide a unified voice for the non-imaging vascular testing
 industry
 -- Open lines of communication among manufacturers, distributors,
 doctors and related people in the vascular testing industry
 -- Ensure proper representation for their industry during
 healthcare reform discussions, lobbying for continued access to
 and reimbursement for vascular testing
 -- Provide doctors with timely and up-to-date data concerning
 healthcare reform, clinical applications, training and
 reimbursement issues.
 The first action of the ACCT was to hire Frederick H. Graefe, a healthcare industry lobbyist in Washington. Graefe will represent ACCT members to key legislators and house and administrative agencies.
 For more information on the ACCT, contact Ernie Malachowski at 303-431-9400.
 -0- 7/27/93
 /CONTACT: Dennis Newman of Imex Medical Systems, 303-431-9400; or John Metzger of Metzger Trinske Communications, 303-786-7000 or 303-665-7760, for Imex Medical Systems/
 (IMEX)


CO: Imex Medical Systems Inc.; The Association for Cost-effective
 Cardiovascular Technology ST: Colorado IN: MTC SU:


MC -- DV002 -- 6025 07/27/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:288
Previous Article:CELLEX BIOSCIENCES ENTERS INTO DISTRIBUTION AGREEMENT WITH RECEPTOR TECHNOLOGIES LIMITED OF ENGLAND
Next Article:SORICON ANNOUNCES $1 MILLION IN PURCHASE ORDERS FROM KING SOOPERS AND LARGE NATIONAL CHECK VERIFICATION COMPANY
Topics:


Related Articles
BOSTON SCIENTIFIC AND SCIMED ANNOUNCE AGREEMENT TO MERGE
BOSTON SCIENTIFIC AND SCIMED ANNOUNCE AGREEMENT TO MERGE
Imex Medical Systems Announces Financial Results For Second Quarter 1997
Imex Introduces Revolutionary Vascular Testing System
USS' Vascular Therapies Division Enters $150 Million Cardiovascular Surgery Cannula Market
AVE Signs Agreement With Columbia/HCA
Frost & Sullivan: Small Devices Have Huge Impact on the Interventional Cardiovascular Device Markets.
Dade Behring Introduces Innovative New High-Sensitivity Test to Help Assess Risk of Heart Attack and Stroke.
GenStar Therapeutics Announces Operational Changes to Reduce Expenses And Concentrate Resources on Later Stage Lead Cardiovascular Products of...
Edwards Lifesciences Announces Clinical Trial Initiated for Therapy to Treat Critical Limb Ischemia.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters